| Literature DB >> 29402282 |
Shereen Katrak1, Patience Nayebare2, John Rek2, Emmanuel Arinaitwe2,3, Joaniter I Nankabirwa2,4, Moses Kamya2,4, Grant Dorsey5, Philip J Rosenthal5, Bryan Greenhouse5.
Abstract
BACKGROUND: Submicroscopic malaria parasitaemia is common in both high- and low-endemicity settings, but its clinical consequences are unclear.Entities:
Keywords: Clinical tropical medicine; LAMP; Malaria; Molecular epidemiology; Submicroscopic infection
Mesh:
Year: 2018 PMID: 29402282 PMCID: PMC5800031 DOI: 10.1186/s12936-018-2221-9
Source DB: PubMed Journal: Malar J ISSN: 1475-2875 Impact factor: 2.979
Fig. 1Study enrolment. The study cohort was comprised of 364 children and 106 adults, who made a total of 9075 routine visits to the study clinic. Routine visits were categorized as no parasitaemia (blood smear and LAMP negative), submicroscopic parasitaemia (blood smear negative, LAMP positive), or microscopic parasitaemia (blood smear positive). Visits were further categorized based on whether the participant had a symptomatic episode of malaria within 14 days before or 7 days following the routine visit
Fig. 2Proportion of study population with microscopic and submicroscopic parasitaemia. Participants are divided into age strata along the X axis. The percentage of positive samples, among all samples collected at routine visits for that age group, is shown on the Y axis
Association between parasitaemia and fever
| No parasitaemia | Submicroscopic parasitaemia | Microscopic parasitaemia | |
|---|---|---|---|
| Association between parasitaemia and fevera | |||
| Age 0.5–< 2 | |||
| Risk | 37/293 (12.6%) | 16/120 (13.3%) | 25/71 (35.2%) |
| RRb (95% CI) | Reference group | 1.02 (0.60–1.75) | 2.72 (1.71–4.33) |
| p value | – | 0.08 | < 0.01 |
| Age 2–< 5 | |||
| Risk | 88/1158 (7.6%) | 59/508 (11.6%) | 81/393 (20.6%) |
| RRb (95% CI) | Reference group | 1.42 (1.03–1.98) | 2.56 (1.93–3.37) |
| p value | – | 0.03 | < 0.01 |
| Age 5–10 | |||
| Risk | 86/2153 (4.0%) | 93/1267 (7.34%) | 146/1379 (10.6%) |
| RRb (95% CI) | Reference group | 2.01 (1.49–2.71) | 2.93 (2.15–3.99) |
| p value | – | < 0.01 | < 0.01 |
| Age 0.5–10 | |||
| Risk | 211/3604 (5.6%) | 168/1895 (8.9%) | 252/1843 (13.7%) |
| RRb (95% CI) | Reference group | 1.67 (1.37–2.03) | 2.64 (2.16–3.22) |
| p value | – | < 0.01 | < 0.01 |
| Age ≥ 18 | |||
| Risk | 50/948 (5.2%) | 48/679 (7.1%) | 8/106 (7.6%) |
| RRb (95% CI) | Reference group | 1.31 (0.23–0.85) | 1.47 (0.70–3.06) |
| p value | – | 0.23 | 0.31 |
aReported fever in prior 24 h or documented temperature of ≥ 38.0 °C at routine visit
bAdjusted for repeated measures in the same study participant
cExcludes participants who were diagnosed with malaria in the past 14 days or developed malaria in the next 7 days
Association between parasitaemia and non-febrile clinical illness
| No parasitaemia | Submicroscopic parasitaemia | Microscopic parasitaemia | |
|---|---|---|---|
| Association between parasitaemia and non-febrile clinical illnessa | |||
| Age 0.5–< 2 | |||
| Risk | 74/293 (25.3%) | 27/120 (22.5%) | 31/71 (43.7%) |
| RRb (95% CI) | Reference group | 0.90 (0.60–1.36) | 1.73 (1.28–2.35) |
| p value | – | 0.60 | < 0.01 |
| Age 2–< 5 | |||
| Risk | 181/1158 (15.6%) | 96/508 (18.9%) | 87/393 (22.1%) |
| RRb (95% CI) | Reference group | 1.16 (0.92–1.46) | 1.39 (1.09–1.77) |
| p value | – | 0.22 | 0.01 |
| Age 5–10 | |||
| Risk | 185/2153 (8.6%) | 152/1267 (12.0%) | 191/1379 (13.9%) |
| RRb (95% CI) | Reference group | 1.44 (1.17–1.78) | 1.71 (1.37–2.13) |
| p value | – | < 0.01 | < 0.01 |
| Age 0.5–10 | |||
| Risk | 440/3604 (12.2%) | 275/1895 (14.5%) | 309/1843 (16.8%) |
| RRb (95% CI) | Reference group | 1.26 (1.09–1.47) | 1.52 (1.30–1.78) |
| p value | – | < 0.01 | < 0.01 |
| Age ≥ 18 | |||
| Risk | 119/948 (12.6%) | 94/679 (13.8%) | 12/106 (11.3%) |
| RRb (95% CI) | Reference group | 1.10 (0.82–1.48) | 0.96 (0.52–1.76) |
| p value | – | 0.52 | 0.89 |
aComposite variable based on self-report of abdominal pain, anorexia, vomiting, diarrhea, cough, headache, joint pain, muscle ache, seizure, or jaundice at routine visit
bAdjusted for repeated measures in the same study participant
cExcludes participants who were diagnosed with malaria in the past 14 days or developed malaria in the next 7 days